Similar articles

• Torcetrapib and atorvastatin--should marketing drive the research agenda?

  Avorn J. Avorn J. N Engl J Med. 2005 Jun 23;352(25):2573-6. doi: 10.1056/NEJMp058075. N Engl J Med. 2005. PMID: 15972861 No abstract available.
• Increasing HDL Cholesterol Levels.

  Brewer HB Jr. Brewer HB Jr. N Engl J Med. 2004 Apr 8;350(15):1491-4. doi: 10.1056/NEJMp048023. N Engl J Med. 2004. PMID: 15071124 No abstract available.
• Effect of torcetrapib on the progression of coronary atherosclerosis.

  Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators. Nissen SE, et al. N Engl J Med. 2007 Mar 29;356(13):1304-16. doi: 10.1056/NEJMoa070635. Epub 2007 Mar 26. N Engl J Med. 2007. PMID: 17387129 Clinical Trial.
• Pitavastatin: novel effects on lipid parameters.

  Chapman MJ. Chapman MJ. Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Atheroscler Suppl. 2011. PMID: 22152282 Review.
• Torcetrapib/atorvastatin combination therapy.

  Bays H, McKenney J, Davidson M. Bays H, et al. Expert Rev Cardiovasc Ther. 2005 Sep;3(5):789-820. doi: 10.1586/14779072.3.5.789. Expert Rev Cardiovasc Ther. 2005. PMID: 16181026 Review.